Pain, NOCICEPTION, INFLAMMATORY AND NEUROPATHIC PAIN
====================================================

The ability to recognize and remember danger is one of the major evolutionary steps necessary for survival in a hostile environment. The primary line of defense for organisms relies on the primary nociceptive neurons, which are activated when stimuli intensities reach the noxious range. The peripheral endings of nociceptive neurons are found in almost all tissue of the body, i.e., skin, muscle and internal organs ([@B161]). Their cell bodies are located in the dorsal root ganglia (DRG) or the trigeminal ganglia (TG) for the innervations of the face. Central terminals of primary nociceptive neurons project to the dorsal horn of the spinal cord where they make their first synapse with secondary order sensory neurons and/or interneurons ([@B194]). At this level, the transmission of the signal by the secondary order projection neurons to the supra spinal centers is modulated by a complex network of the dorsal horn. A barrage of activity or neurotransmitter release from the periphery can highly modulate the excitability of the secondary order neurons ([@B167]). Spinal neurons are subjected to change by microglial, astrocytic and oligodendrocitic cells ([@B102]; [@B181]). Furthermore, descending projections from supra-spinal centers can affect the central terminal of the primary sensory neuron, the projection neuron and the inhibitory and excitatory interneurons. The signal is eventually processed and reaches supra-spinal centers, including brain areas involved in sensory and emotional pain perception. At this point, complex circuitries process and integrate the pain signal and allow for appropriate behavioral and motor responses. These circuitries also modulate pain signaling via descending pathways that ultimately reach the dorsal horn neurons.

For the most part, primary nociceptive neurons are polymodal ([@B85]), in that they are able to detect a wide range of stimuli, such as heat and mechanical or chemical stimuli. To integrate these wide ranges of stimuli, nociceptive neurons express a multitude of receptors and ion channels in their free endings ([@B15]). There are many review articles that extensively discuss these so called transducers, i.e., TRP channel family members or acid-sensing ion channels (ASICs; [@B15]; [@B260]; [@B72]). Once transducers are activated, these non-selective ion channels open and contribute to cell depolarization, thus eliciting an action potential (AP) and allowing for the transmission of a noxious signal along pain pathways.

Nociception enables the organism to react quickly, and by virtue of the emotionally offensive component of pain, helps the organism avoid similar situations in the future. When the noxious stimulus is acute, pain is transient and the nociceptive neurons should subsequently return to a resting state. This process is referred to as **nociception**. On the other hand, tissue injury leads to longer lasting inflammatory pain, characterized by peripheral sensitization. **Inflammatory pain** is due to the modification of the chemical environment surrounding nociceptive neurons and the accumulation of several factors secreted by recruited non-neural cells, such as mast cells, macrophages, neutrophils, inflammatory cells, fibroblasts and keratinocytes, as well as by the nociceptive neurons themselves. These factors are of diverse origins but include protons (H^+^), nerve growth factors (NGFs), cytokines (such as IL-1β, IL-6), tumor necrosis factor alpha (TNF-α), prostaglandins (PGE~2~), several neurotransmitters (serotonin, ATP) and peptides (bradykinin, substance P, CGRP). This mixture is commonly referred to as "the inflammatory soup" ([@B15]), and will increase spontaneous neuronal firing, usually decrease the threshold of nociceptive neurons and increase firing in response to suprathreshold stimuli. The mechanisms by which inflammatory pain increases pain transmission include the activation of kinases that phosphorylate membrane channels and receptors, which subsequently alter their function, and the genetic regulation of primary sensory neurons ([@B293]). Inflammatory pain, by the virtue of central sensitization, is also accompanied by the local loss of inhibition ([@B147]) and enhanced postsynaptic transmission ([@B106]).

Inflammatory pain is linked to the persistence of inflammation, but should fade away when the tissue is healed. In some cases, however, abnormal activity from the peripheral neurons can also occur in the absence of tissue inflammation. This abnormal activity occurs when nociceptive neurons are damaged and elicit long-term molecular modifications that eventually lead to **neuropathic pain**. Neuropathic pain is defined as the "pain caused by a lesion or disease of the somatosensory system" ([@B118]). This definition reflects that not only nerve injury, but also degenerative, infectious or metabolic conditions can lead to neuropathic pain, accounting for the distinct etiologies of peripheral neuropathic pain (e.g., compressive disk herniation, diabetic neuropathy, chemotherapeutic-induced neuropathy, post-herpetic neuralgia, etc.) ([@B294]). The prevalence of neuropathic pain varies from 7 ([@B32]) to 18% of the population ([@B271]). Most of these patients are often resistant to treatment ([@B35]). Neuropathic pain cardinal positive symptoms are spontaneous pain, allodynia and hyperalgesia, but can be also associated with negative symptoms such as hyposensitivity in a related nerve territory. Spontaneous pain is thought to arise from ectopic activity, which can be driven by C- ([@B81]) and A-fibers ([@B175]); where as allodynia and hyperalgesia are related to reduced activation thresholds or an increased response of primary afferent neurons ([@B279]). The peripheral mechanisms underlying neuropathic pain associated hyperexcitability have been extensively reviewed in other articles ([@B147]; [@B291]; [@B38]; [@B129]). These mechanisms include altered gene expression, dysregulation of membrane channel expression, migration of inflammatory cells and activation of satellite cells in DRG neurons. The increased peripheral input leads to activity-dependent mechanisms of central sensitization in the spinal cord and supra-spinal levels ([@B295]; [@B167]; [@B292]). Although they share similar pain symptoms and some common mechanisms, inflammatory and neuropathic pain differ fundamentally by their respective pharmacology and resolution. Altogether, peripheral and central mechanisms will lead to enhanced and long-lasting pain perception, which will ultimately result in debilitating chronic conditions, sleep disturbances, depression, anxiety and social withdrawal ([@B14]; [@B272]). On the other side of the spectrum, in diseases where patients can no longer experience pain appropriately, such as in congenital insensitivity to pain, the pain signal is permanently shut off. This results in an inappropriate behavioral response and a reduced life expectancy in a subset of individuals ([@B203]).

Na~v~s: Structure And Function
==============================

After activation via transducers, primary nociceptive neurons transmit the signal along the axon to the spinal cord. Voltage-gated sodium channels (Na~v~s) play a critical role in this process. Na~v~s are activated upon depolarization of the transmembrane voltage, generating a fast, transient and massive inward sodium current, which accounts for the rising phase of the AP. Na~v~s give rise to the upstroke of the AP and contribute to setting the resting membrane potential of nociceptive neurons ([@B120]; [@B234]).

Since the first biochemical characterization of Na~v~s ([@B18]), tremendous effort has been made to unravel the structure and function of the sodium channel. The α-subunit is encoded by a single gene, which is structurally divided into four homologous domains (I-IV) connected by an intra and/or extracellular loop, thus referred to as heterotetramere. Each domain is composed of six α-helical transmembrane segments. S5 and S6 compose the pore of the channel, whereas S1 -- S4 are the voltage sensors. The crystallography structure of Na~v~Ab, a bacterial sodium channel from *Arcobacter butzleri*, was identified in 2011 ([@B213]). Although Na~v~Ab is a homotetramere and the mammalian Na~v~s is heterotetrameric, they share similar pharmacological profiles ([@B228]). Most of the inferences made based on previous biochemical and electrophysiological experiments have been confirmed ([@B213]).

Nine discrete genes (*SCNxA*) encode for the α-subunits (Na~v~1.1 to Na~v~1.9 isoforms) ([@B43]) and another atypical tenth isoform, NaX ([@B9]; [@B207]). Each isoform has its own biophysical properties and particular expression pattern across the nervous system. A single amino acid substitution in the S5--S6 linker renders Na~v~1.5, Na~v~1.8, and Na~v~1.9 resistance to TTX.

α-subunits are accompanied by associated β-subunits with an assumed stoichiometry for an α-β association of 1:1 ([@B44]). There are four different identified genes coding for the different β-subunits: *SCN1B* codes for β1 ([@B134]) and its associated splice variant β1A ([@B149]); *SCN2B* codes for β2 ([@B135]); *SCN3B* codes for β3 ([@B199]) and *SCN4B* codes for β4 ([@B308]). The pore-forming α-subunit enables for Na^+^ conductance, but the β--subunits can modulate the biophysical properties and plasma membrane stabilization of Na~v~s ([@B136]).

Na~v~1.7, Na~v~1.8, and Na~v~1.9 Are Expressed In Nociceptive Neurons
=====================================================================

Na~v~s are broadly expressed in excitable cells throughout the body, with some isoforms ubiquitously expressed and others expressed in specific tissues. In nociceptive neurons, many of the different Na~v~s isoforms are present and collaborate with one another for electrogenesis. With the exception of Na~v~1.2 and Na~v~1.4, all the Na~v~ isoforms are expressed in DRG nociceptive neurons ([@B28]; [@B234]; [@B22]; [@B104]; [@B105]; [@B124]). The role of Na~v~1.5 in adult small DRG neurons has not been fully unraveled ([@B229]). As compared to Na~v~1.1 and Na~v~1.6, the Na~v~1.7 isoform is the most expressed TTX-sensitive isoform among the DRG neurons ([@B28]; [@B269]; [@B22]; [@B124]; [@B77]). The two TTX-resistant isoforms, Na~v~1.8 and Na~v~1.9, are also highly expressed in nociceptive neurons ([@B7]; [@B76]). During the last decade, mutations in Na~v~1.7, Na~v~1.8, and Na~v~1.9 have been linked with human pain disorders (see Inherited Pain Syndromes). The possible variable combinations of each of these "pain specialized" isoforms, as well as their relative expression levels, differentially shape the AP and firing properties, accounting for the heterogeneity among DRG neurons ([@B234]; [@B266]). In this review, we focus on the roles of Na~v~1.7, Na~v~1.8, and Na~v~1.9 in chronic pain states.

Na~v~s' Implication In Pain Syndromes
=====================================

Reviewing all the studies that have investigated the Na~v~1.7, Na~v~1.8, and Na~v~1.9 mutations associated with painful channelopathies and those studies that have investigated the expression of Na~v~s in human and animal models of pathological pain is beyond the scope of this review and can already be found in other recent reviews ([@B34]; [@B286]; [@B287]; [@B126]). In the next two chapters we will summarize some of the key findings demonstrating the role of Na~v~s in channelopathies and in animal models of inflammatory pain, and we will discuss conflicting results observed in neuropathic pain in both human and animal studies.

Inherited Pain Syndromes
------------------------

The contribution of Na~v~1.7, Na~v~1.8, and Na~v~1.9 in chronic pain syndromes is exemplified through human mutations (familial and *de novo* mutations) of these channels and their associated pathologies, being either pain hypersensitivity or congenital insensitivity to pain ([@B73]; [@B176]; [@B286]). Seminal studies have linked Na~v~1.7 to altered pain sensitivity. A gain of function for this gene leads to inherited painful channelopathies, such as erythromelalgia ([@B64]; [@B304]) and paroxysmal extreme pain disorder ([@B98]). Conversely, a loss of function for Na~v~1.7 was reported to be associated with congenital insensitivity to pain ([@B61]). Many other studies have identified Na~v~1.7 mutations as being implicated in numerous altered pain sensation pathologies ([@B75], [@B77]; [@B285]; [@B98]; [@B208]; [@B52]). A gain of function mutation of Na~v~1.9 was linked to an episodic pain disorder ([@B313]); while another gain of function mutation of Na~v~1.9 was reported to cause a loss of pain perception ([@B168]). In the latter the authors showed that the excessive activity of Na~v~1.9 at resting voltages caused sustained depolarization of nociceptive neurons, leading to the inactivation of other Na~v~s and subsequently to the impairment of the AP generation. Other studies also highlighted a role of Na~v~1.7 in idiopathic small-fiber neuropathy (I-SFN); nearly 30% of patients suffering from this pathology had a gain of function mutation in Na~v~1.7 ([@B92]). Small fiber peripheral neuropathy is a type of peripheral neuropathy that occurs from damage to C-fibers and A-δ fibers, which can often lead to exaggerated pain sensitivity ([@B127]). Since these first studies, similar gain of function mutations in Na~v~1.8 and Na~v~1.9 have been reported in I-SFN ([@B93]; [@B117]; [@B128]). None of the previous gain of function mutations of Na~v~1.7, Na~v~1.8, and Na~v~1.9 have been studied in animal models of chronic pain.

Acquired Pain Syndromes
-----------------------

Apart from intrinsic modifications of Na~v~ channel function, a modification of expression levels will also impact neuronal excitability. Most of the studies that are discussed here investigated Na~v~ expression while assuming that an increased sodium channel expression and conductance would cause neuronal hyperexcitability, something already demonstrated by computer simulations ([@B190]). However, the link between increased sodium channel expression and hyperexcitability is likely more complex. For instance, computational studies revealed that increasing the sodium conductance might actually decrease the firing rate of neurons ([@B155]). In addition, a gain of function mutation of Na~v~1.9 was recently shown to be associated with congenital insensitivity to pain ([@B168]).

Modifications in Na~v~1.7, Na~v~1.8, and Na~v~1.9 expression have been observed in several chronic pain syndromes. Both human studies and experimental pain model studies have helped unravel the role of these isoforms in chronic pain syndromes, including both inflammatory and neuropathic pain.

There is substantial evidence linking Na~v~1.7 to inflammatory pain in animal studies. Studies have reported an increase of Na~v~1.7 expression after injection of pro-inflammatory mediators ([@B115]; [@B29]). Knocking-down Na~v~1.7 in a model of inflammatory pain with a viral vector in primary afferents ([@B305]) led to the attenuated development of hyperalgesia, a result confirmed by another study using Na~v~1.7 knockout mice ([@B205]). Similarly to Na~v~1.7, knocking down ([@B151]) or knocking out Na~v~1.8 ([@B151]; [@B8]) prevented full development of pain hypersensitivity in inflammatory pain models. Na~v~1.8 was also shown to be increased in inflammatory pain models ([@B55]; [@B259]), and its role was confirmed in knockdown studies ([@B309]) and in studies using specific blockers ([@B139]; [@B197]). Other studies also support a role for Na~v~1.9 in inflammatory pain ([@B74]). Na~v~1.9 knockout mice or knockdown rats have a weaker response to inflammatory mediator application ([@B122]; [@B222]; [@B12]; [@B178]; [@B125]).

Dysregulated Na~v~ expression, by altering the intrinsic electrical properties of neuronal plasma membranes, is largely accountable for neuropathic pain-associated hyperexcitability ([@B191]; [@B312]). Na~v~s' contribution to neuropathic pain is also demonstrated by the application of local anesthetics known to block sodium channels, which suppresses ectopic discharges and attenuates allodynia and hyperalgesia ([@B189]; [@B262]; [@B246]).

The development of nerve injury-induced neuropathic pain animal models has significantly contributed to the discovery of mechanisms that contribute to neuropathic pain syndromes, but also gave rise to conflicting results. For instance, the role of Na~v~1.7 in neuropathic pain is still being debated. Na~v~1.7 mRNA is reduced after peripheral nerve injury-induced neuropathic pain in rats ([@B22]; [@B165]; [@B42]), an observation confirmed by reduced levels of the Na~v~1.7 protein. Furthermore, Na~v~1.7 knockout mice still develop neuropathic pain-mediated mechanical allodynia ([@B205]). More recent studies suggest that Na~v~1.7 is actually implicated in neuropathic pain by virtue of its concomitant expression in both sympathetic ganglion neurons and nociceptive neurons, rather than solely in nociceptive neurons ([@B195]). In contrast, other studies have reported an increased expression of Na~v~1.7 mRNA in DRG neurons ([@B173]), as well as an increased protein expression in the sciatic nerve of animal experimental neuropathic pain models ([@B162]). In humans, many studies reported an increased expression of this isoform, such as in intervertebral disk injury ([@B237]), human dental pulp neuromas ([@B183]) and other neuromas ([@B59]; [@B160]; [@B26]; [@B215]).

Na~v~1.8 regulation is also controversial in experimental nerve-injury induced neuropathic pain. Many studies have reported a downregulation of Na~v~1.8 mRNA ([@B284]; [@B22]), protein ([@B69]) and currents ([@B65]; [@B22]) in rodent models. Another group, however, reported an increase of the Na~v~1.8-mediated current ([@B1]). To reconcile these contradictory findings, it was suggested that a decrease in the expression of Na~v~1.8 mRNA and protein in the cell soma of nociceptive neurons could be due to a redistribution of this isoform in the sciatic nerve ([@B113]; [@B265]). Controlling Na~v~1.8 expression in mice also leads to controversial results. Gene knockout studies did not find a role for Na~v~1.8 in neuropathic pain development ([@B8]; [@B150]; [@B2]), whereas gene knockdown speaks in favor of such a role ([@B166]; [@B83]; [@B169]). It is likely that Na~v~1.8 involvement depends on the type of lesion and the model of chronic pain ([@B146]). A few studies carried out in humans showed that Na~v~1.8 expression was increased in neuromas ([@B160]; [@B30]; [@B25]).

Na~v~1.9 implication in neuropathic pain has been scarcely investigated. A few studies reported a downregulation of Na~v~1.9 mRNA and protein in animal models of neuropathic pain ([@B76]; [@B69]; [@B22]; [@B165]; [@B42]; [@B306]). A human study reported no modification of Na~v~1.9 protein in patients with lingual nerve neuromas ([@B25]).

The conflicting observations of sodium channel regulation in animal models of neuropathic pain underscores that further research is necessary to clarify the mechanisms leading to Na~v~s dysregulation and to those that generate hyperexcitability. Some of the aforementioned discrepant results can be attributed to the use of different models of pathological pain, the different species used, the relocalization of mRNA or protein, and/or various compensation mechanisms. Some of these studies analyzed the total pool of cellular Na~v~s, but only Na~v~s anchored at the membrane regulate the electrogenesis of nociceptive neurons. There is a large pool of intracellular Na~v~s in the trafficking pathway ([@B244]), and it is possible that a modification of the membrane fraction can be overshadowed if one looks at the overall cellular pool of sodium channels. Furthermore, it remains possible, that an apparent decrease of total Na~v~ expression in a cell is concomitant with an increase membrane expression of sodium channels. Studying mechanisms that regulate the trafficking of a channel, or mechanisms that directly alter the biophysical properties of a channel, might reconcile these discrepant results.

Post Translational Modifications
================================

Both acquired and inherited pain syndromes are manifestations of altered function and expression of Na~v~s that result in electrical instabilities in the nociceptive pathway, ultimately leading to pathological pain. In channelopathies, the pain syndrome is due to a DNA mutation that can be either sporadic or inherited. In acquired pain syndromes, the altered expression and function can be due to a plethora of signaling pathway activations. Among them, post-translational modifications (PTMs) are important contributors to the development of chronic pain syndromes.

Post-translational modifications are protein modifications that occur either soon after the ribosome-mediated translation of the mRNA into a polypeptide chain or later in the secretory pathway. These are critical steps for protein maturation and function. In these processes, many different enzymes attach biochemical groups (acetylation, phosphorylation), polypeptides (ubiquitylation, SUMOylation) and complex molecules (glycosylation, isoprenylation), or cleave (proteolysis) a protein's specific amino acid. The overall effect of PTMs leads to a modulation of the structure, function or localization of the given protein. PTMs were first identified in the study of kinases ([@B131]) and protein degradation ([@B54]; [@B158]) many decades ago. Since then the number of different PTMs has risen to over 200 ([@B188]). PTMs are involved in almost every cellular event, from precise gene expression regulation to broad signal integration ([@B70]).

Post-translational modifications have a large spectrum of action on proteins, ranging from very stable modifications to very transient and reversible changes. For instance, glycosylation and disulfide bridge formation are directly implicated in the synthesis, maturation and folding of the protein. The covalent binding of molecules, such as the addition of a ubiquitin moiety, leads to quicker and stable protein modification. On the other side of the spectrum, some PTMs are versatile and are important for transient cellular signaling, as exemplified by the phosphorylation process.

There is precise coupling between the interaction sites of PTMs and a given amino acid sequence on the target protein, rendering the system very specific. This also allows for good spatial (many different amino acids can be targeted by the same PTM) and temporal (a given amino acid can be modified by different PTMs) control and allows neurons to fine tune the properties of a protein depending on the changes occurring in the direct environment.

Ptms Alter Na~v~ Function And/Or Expression
===========================================

Computational studies have shown that, depending on the site of phosphorylation, the addition of a phosphoryl group that carries two negative charges at physiological pH ([@B204]) can modify the structure and the function of the protein through an alteration of the free energy landscape. Na~v~s possesses charged residues in the voltage sensor domain that can sense membrane potential oscillation. When the transmembrane voltage changes, these charged domains reorient in the electric field resulting in conformational changes, a process referred to as gating. The addition of charged groups on their intra-cellular, extra-cellular or transmembrane domains modifies protein intrinsic properties and functions. Apart from the direct electrostatic effect on gating of the channels, phosphorylation can also create or disrupt binding sites for interaction with other regulatory proteins that modulate Na~v~ function.

Na~v~s need to be at the interface between a high extracellular and low intracellular sodium concentration to open and drive sodium influx. For this reason they are only functional when anchored at the plasma membrane. There is also, however, a large intracellular pool of Na~v~s in the secretory pathway of the cell ([@B244]; [@B231]). A tight balance between the membrane and the intracellular pool, a process referred to as trafficking, is crucial for the fine-tuning of cellular excitability in nociceptive neurons. Maintaining this equilibrium is largely mediated by PTMs that regulate the trafficking of Na~v~s ([@B66]). Some enzymes will generate PTMs that are responsible for internalization and/or degradation, whereas others will promote externalization or stabilization of Na~v~s at the membrane.

Peripheral Sensitization Triggers Ptms
======================================

We previously highlighted that peripheral sensitization is triggered by the inflammatory soup ([@B15]). There is a large body of evidence that there is a recruitment of macrophages ([@B214]) and neutrophils ([@B67]), as well as degranulation of mast cells ([@B212]; [@B319]) in inflammatory processes, such as the ones observed after nerve injury. Once recruited, these cells secrete peptides, such as prostaglandins (PGE~2~), bradykinin, NGF and serotonin ([@B45]; [@B217]). They also secret cytokines, such as TNF-α or IL-1β and IL-6 ([@B289]). Some of these mediators are not only secreted by immune or inflammatory cells, but also by the nociceptive neurons themselves ([@B67]). When inflammation resolves, these molecules are slowly cleared from the extracellular liquid around nociceptive neurons. In some cases, however, pro-nociceptive molecules, such as NGF and cytokines, ([@B170]; [@B82]; [@B108]) are found to persist at the site of injury. This phenomenon may partially explain any long-term changes.

When binding to receptors, which include neurotrophic tyrosine kinase receptors (NTKR), such as TrkA, and/or G-protein coupled receptors (GPCRs), such as bradykinin and PGE2 receptors, these aforementioned ligands (peptides and cytokines) will activate multiple intracellular pathways, including Protein Kinase A (PKA), Protein Kinase B (PKB), Protein Kinase C (PKC), Mitogen-activated protein Kinase (MAPK) and the Ca++/Calmodulin-dependent Kinase I and II (CamKI/II), among others (**Figure [1](#F1){ref-type="fig"}**). The concrete, but not sole, effect of these cascades is phosphorylation or other PTMs of Na~v~s ([@B74]), which lead to long-term increased neuronal excitability. It should, however, be noted that PTMs also control other ion channels, such as potassium channels, and even modulate the activation of some transcription factors. They might also regulate nociceptive neuronal excitability through these alternative mechanisms.

![**Scheme representing the peripheral terminal, axon and cell soma of a pseudo-unipolar dorsal root ganglia nociceptive neuron, in normal and pathological pain conditions.** Following tissue damage and inflammation, recruited inflammatory cells secrete numerous pro-inflammatory molecules (referred to as the inflammatory soup). These chemical mediators activate many membrane proteins, including G-protein coupled receptors (GPCR), neurotrophic tyrosine kinase receptors (NTKR) and cytokines receptors (CR). GPCR binding by PGE2 and bradykinin mostly leads to protein kinase A (PKA) and protein kinase C (PKC) activation, through the adenylate cyclase (AC) and inositol 3-phosphate (IP3) secondary messengers, respectively. NTKR and CR binding by TNFα, IL-6 and NGF will activate ERK1/2 and p38 kinases via different potential secondary messengers. These signal transduction pathways can undergo cross communication one with another. In experimental neuropathic pain, nerve injury induces Nedd4-2 downregulation. In models of diabetic neuropathy, as well as in patients, methylglyoxal accumulation is related to an increased glucose concentration. The increased activation of kinases, the downregulation of Nedd4-2 and the accumulation of methylglyoxal all lead to an increase of Na~v~1.7/Na~v~1.8 function (shift of biophysical properties, making the channel more available, as represented in green and red in the figure) and/or to an increase of Na~v~1.7/Na~v~1.8 expression at the membrane (altered trafficking), which leads to increased sodium influx and consequently to nociceptive neuronal hyperexcitability.](fphar-06-00263-g001){#F1}

Protein Kinases
===============

Phosphorylation is an important PTM that affects up to 30% of proteins *in vivo* ([@B157]). The phosphate group is usually added to serine, threonine, histidine, and tyrosine residues in eukaryotic proteins. The effect of protein kinases (PKs) on Na~v~s in peripheral chronic pain syndromes has been extensively reported in the literature. The reports are varied and complex, largely due to the important number of phosphorylation sites and to the large number of different PKs present in nociceptive neurons. PKs can modulate Na~v~ function in a very short-term range upon electrostatic interferences. Phosphate groups carry a -2 charge at physiological pH that might interfere with the Na~v~s voltage-sensing domain, or other domains implicated in the gating of the channel. PKs can also have long-term effects when regulating Na~v~ trafficking, which is acheived by masking or highlighting targeting sequences, such as the endoplasmic reticulum (RE) retention signal of Na~v~s ([@B315]).

Protein Kinase A
----------------

The immediate increase in nociceptive neuronal excitability observed after tissue injury or inflammation results from G-protein-coupled receptor activation and the resulting intracellular signaling pathway ([@B293]). G-protein binding leads to an increase in cAMP production by adenylate cyclase (AC), which ultimately activates PKA. Triggering of this pathway by direct cAMP application or activation of AC is sufficient to elicit hyperalgesia in animals ([@B263]; [@B159]; [@B129]). PKA activation not only plays a role in the initiation of pain hypersensitivity, but is also important for the maintenance of inflammatory pain ([@B10]). PGE~2~ is one of the best-known ligands that activates this pathway. PGE~2~ binds to the prostaglandin E~2~ receptor (E~2~) and increases cAMP in sensory neurons ([@B219]). Many studies have reported that PGE~2~-induced hyperalgesia is due to PKA activation ([@B220]; [@B153]; [@B89]).

Protein kinase A phosphorylates Na~v~1.2 in brain neurons ([@B57]; [@B232]), with the main effect being a 50% reduction in the peak current ([@B110]), along with modifications of some biophysical properties ([@B171]; [@B251]). This suggests that both the function and expression of Na~v~1.2 are modified by PKA. Since these early studies, other groups have reported similar decreases in Na~v~1.1, Na~v~1.6, and Na~v~1.7 in different cell expression systems and intact cells ([@B110]; [@B41]; [@B252]; [@B316]; [@B276]; [@B51]; [@B177]). The phosphorylation sites of Na~v~1.2 by PKA were mostly investigated using traditional biochemical approaches ([@B201]; [@B251]; [@B41]). A lot of new predictive bioinformatic tools have helped identify phosphorylation sites on other isoforms.

Protein kinase A is increased after inflammation and in pathological pain states. [@B276] showed that PKA decreases Na~v~1.7. One could hypothesize, therefore, that inflammation may decrease nociceptive neuronal excitability through Na~v~ downregulation. However, Na~v~1.7, as well as other Na~v~ isoforms, can undergo alternative splicing, with each splice variant possessing distinct biochemical and pharmacological properties ([@B240]; [@B221]; [@B78]; [@B243]). It was previously shown that a particular Na~v~1.7 splice variant, Na~v~1.7 11S, was upregulated and responsible for pain hypersensitivity in animal models of neuropathic pain ([@B226]). Contrary to the lack of effect of PKA on three spice variants, the Na~v~1.7 11S splice variant activation curves were shifted to hyperpolarized potentials upon PKA activation, thus lowering the threshold for opening of the channel and presumably increasing neuronal excitability ([@B48]). The current hypothesis is that in chronic pain syndromes the increase of this splice variant, together with the modification of its biophysical properties by PKA, will lead to an increase in sodium conductance which results in nociceptive neuronal hyperexcitability. One must keep in mind that the effect of PKA on Na~v~1.7 was found in *Xenopus* oocytes and other mammalian cell lines, which have a different cellular background than nociceptive neurons, and that Na~v~ regulation varies greatly depending on cell type ([@B63]). This is highlighted by one Na~v~1.7 mutation that renders DRG sensory neurons hyperexcitable, but decreases sympathetic DRG neuron excitability ([@B235]). Studying an endogenous Na~v~1.7 current in adrenal chromaffin cells revealed that cAMP upregulates Na~v~1.7 ([@B310]). Thus, a careful characterization of PKA's effect on the Na~v~1.7 current in nociceptive neurons needs to be performed.

The effect of PKA on TTX-resistant isoforms is the opposite to that aforementioned. PKA increases the TTX-resistant current ([@B112], [@B111]) in DRG neurons, an effect at least partially due to PGE~2~ ([@B89]). A similar increase in the Na~v~1.8 current isolated from a recombinant protein expressed in *Xenopus* oocytes ([@B276]) and mammalian cells ([@B100]) was also reported, providing evidence that PKA activation in pathological pain states can generate nociceptive hyperexcitability through enhanced Na~v~1.8 expression and function. How PKA increases the Na~v~1.8 current is partially due to increased membrane trafficking, since blocking protein transports in DRG neurons prevented a PKA-induced increase of the Na~v~1.8 mediated current ([@B174]). Furthermore, using a site-directed mutagenesis approach, the authors proposed that the forward trafficking effects of Na~v~1.8 could be due to the phosphorylation of an identified ER retention signal.

Na~v~1.9 is also increased by inflammatory mediators ([@B184]), such as PGE~2~. This mechanism is dependent on G-protein activation ([@B236]) and GTPγS ([@B275]).

Protein Kinase B
----------------

The PKB (also referred to as Akt) is well-known for its role in neuronal plasticity in the brain ([@B239]), but little is known about its role in the pain field. There is evidence, however, that PKB is activated in sensory neurons in animal models of neuropathic pain ([@B297]; [@B249]) and inflammatory pain ([@B317]; [@B261]). Furthermore, intrathecal injection of a PKB inhibitor attenuated formalin and carrageenan-induced hypersensitivity ([@B300]). The authors demonstrated that this effect was due to mTOR signaling in the spinal cord, but the intrathecal injection mode of delivery cannot rule out an additional effect in the peripheral nervous system. A recent study showed that PKB activation in peripheral sensory neurons was necessary for the inflammatory-induced increased expression of both Na~v~1.7 and Na~v~1.8 ([@B172]) since blocking this kinase reversed the upregulation of both isoforms. The previous study did not demonstrate that PKB could directly phosphorylate Na~v~s, nor has any other study to our knowledge. However, ASICS, another important ion channel implicated in pain processing, can be directly phosphorylated by PKB, leading to increased trafficking and enhanced expression of ASICs at the membrane ([@B84]). Further investigations are required to unravel the role of PKB in the phosphorylation of Na~v~ channels in pathological pain.

Protein Kinase C
----------------

The implication of PKC activation in nociceptive neurons has been extensively studied. Activation of PKC by phorbol esters demonstrated an *in vivo* implication of this pathway in peripheral sensitization ([@B224]; [@B241]; [@B256]). PKC inhibition decreased hyperalgesia in a model of diabetic neuropathy. Together with PGE~2~, bradykinins are also able to activate PKC pathways ([@B46]; [@B97], [@B96]). PKC is a serine/threonine kinase, which has at least 12 different isoforms ([@B288]) that can be classified into different groups ([@B16]). PKC𝜀 is one of the isoforms shown to be necessary for the development of hypersensitivity in animal models of peripheral chronic pain ([@B152]; [@B11]; [@B79], [@B80]). Inflammatory molecules enhance the translocation of PKC**𝜀** to the membrane, where it contributes to peripheral sensitization ([@B152]; [@B129]; [@B311]). Other PKC isoforms have also been implicated in chronic pain, but focus has been on their expression in the spinal cord.

As for PKA, the phosphorylation of Na~v~1.2 by PKC ([@B58]) could be responsible for a reduction of up to 80% of the current when expressed in *Xenopus* oocytes, with a concomitant slowing of its inactivation ([@B209]). This reduction is due, at least in part, to a positive shift in the voltage-dependence of activation ([@B68]). Similar findings on the total sodium current have been observed in rat brain neurons ([@B209]; [@B40]). Other studies in *Xenopus* oocytes have shown that PKC downregulates the skeletal muscle sodium channel Na~v~1.4 ([@B17]), the cardiac channel Nav1.5 ([@B202]), as well as the two pain specialized isoforms Na~v~1.7 and Na~v~1.8 ([@B276]). It was initially hypothesized that PKC robustly downregulates Na~v~s across species since a reduction in the Na~v~1.5 current was also observed in myocytes and CHO cells ([@B223]), and a reduction in the total sodium current was observed in neuroblastoma cells ([@B230]), hippocampal neurons ([@B40]), and cortical neurons ([@B196]).

As with PKA activation, the decrease of the Na~v~1.7 current mediated by PKC activation ([@B276]) is discrepant with the increased excitability observed in pathological pain. Again, the cellular background studied could explain these discrepancies. Furthermore, a study reported that blocking PKC phosphorylation was concomitant with a decrease in Na~v~1.7 protein expression upon continuous opioid administration in a diabetic painful neuropathic model ([@B49]). In addition, a recent study also showed that PMA activation of PKC pathways led to an increase of Na~v~1.7 resurgent currents in HEK cells ([@B264]), currents which have been implicated in pathological pain ([@B138]).

[@B112], [@B111]) observed that the activation of PKC increased the TTX-resistant current in nociceptive neurons. This was later confirmed by another group ([@B132]). A later study determined which PKC isoform and which of the two TTX-resistant isoforms were responsible for the increased current, implicating PKC𝜀 and Na~v~1.8 ([@B39]). The PKC𝜀 mediated upregulation of Na~v~1.8 was confirmed in another study, demonstrating the causative link to hyperalgesia ([@B296]). Since PGE~2~ can activate the PKC pathway and increase the Na~v~1.9 current in nociceptive neurons ([@B236]), it is likely that both Na~v~1.8 and Na~v~1.9 are implicated. Na~v~1.8 and Na~v~1.9 are well-identified sodium channels whose expression and function are increased upon pathological pain-driven PKC activation. The role of Na~v~1.7, however, remains to be fully elucidated. Since PKA and PKC pathways converge and co-regulate Na~v~1.2 function ([@B47]), similar mechanisms might also account for the effects on Nav1.7, Na~v~1.8 ([@B111]) and Na~v~1.9.

MAPK Pathway
------------

Mitogen-activated protein kinases are another family of kinases that play an important role in mammalian cell signaling. There are three major members in the MAPK family: ERK, p38 and c-JUN. Each member activates a specific intracellular pathway ([@B290]). They regulate various cellular activities and have been implicated in numerous human diseases, including tissue injury ([@B154]). Since they are activated by proinflammatory cytokines ([@B140]), they have been shown to be important in pathological pain ([@B211]).

In transected axons of experimental neuromas, Na~v~1.7 accumulates with ERK1/2 at the site of injury ([@B215]). Since ERK1/2 was shown to phosphorylate Na~v~1.7, altering its biophysical properties and rendering it easier to open in response to stimuli ([@B257]), it is hypothesized that a Na~v~1.7 and ERK1/2 co-accumulation would increase nociceptive neuronal firing. Another study proposed that IL-6 application enhances the excitability of trigeminal ganglion neurons via ERK-mediated phosphorylation of Na~v~1.7, a mechanism involved in the development of migraine-related pain behavior ([@B301]).

Another kinase of the MAPK, p38, was reported to be increased in animal models of neuropathic pain ([@B211]; [@B298]), leading to the upregulation of TTX-resistant sodium channels in sensory neurons ([@B142]). A study recently unraveled the role of TNF-α in activating p38, resulting in the modification of the slow inactivation and voltage dependence of activation of Na~v~1.8/Na~v~1.9. This, in turn, increases the TTX-resistant inward current and enhances nociceptive hyperexcitability ([@B116]). Another study showed that p38 phosphorylates Na~v~1.8, increasing the trafficking of this channel at the membrane of DRG neurons ([@B130]).

Similar to the previous studies investigating MAPK activation in animal models of chronic pain and those focusing on the regulation of Na~v~1.7 and Na~v~1.8 by kinases *in vitro*, ERK1/2 and p38 are increased along with the Na~v~1.7 and Na~v~1.8 isoforms in painful human neuromas ([@B30]), where they likely also contribute to neuronal hyperexcitability.

CamKII
------

Calmodulin (CaM) is a small calcium-binding protein that senses Ca^2+^ changes and drives cellular responses to rapid changes in intracellular calcium concentration. It is also known to be involved in regulating Ca^2+^-dependent neuronal plasticity ([@B255]).

The C-terminus of Na~v~s contains a CaM-binding domain, known as the IQ motif ([@B200]), which is a recognizable site for these calcium-sensing proteins. Even though the functional meaning of such binding remains unknown, there are a few studies reporting the regulation of Na~v~ currents by CaM. Despite the fact that all Na~v~s possess a conserved IQ motif, the regulatory effect of CaM is isoform specific, as exemplified by the more potent regulation of Na~v~1.4 as compared to Na~v~1.5 by this protein ([@B71]; [@B307]; [@B27]; [@B19]). CaM also regulates Na~v~1.6, which is expressed in nociceptive neurons ([@B121]). Interestingly, Na~v~1.7 is also bound by CaM ([@B121]), but with a lower affinity than Na~v~1.6.

CaM Ca^2+^-dependent activation leads to the activation of many signaling molecules, one being the Ca^2+^/CaM-dependent serine/threonine kinase (CamK) ([@B206]). CamKII is expressed in nociceptive neurons and is involved in pain transmission ([@B123]; [@B36]). It was proposed that CamKII is responsible for the transition from acute to chronic pain, a process involving PKC𝜀 activation ([@B95]) and links these two kinase pathways. Further evidence supporting a role for CamKII in neuropathic pain was demonstrated by using a CamKII inhibitor that reversed mechanical allodynia in animal models of both neuropathic pain ([@B50]) and inflammatory pain ([@B182]).

Since the CaM binding effect on Na~v~s regulation is thought to be due to the recruitment and subsequent phosphorylation of Na~v~s by CamKII ([@B71]; [@B187]), it is likely that the activation of this kinase in pathological pain states is partially responsible for hyperexcitability through the regulation of Na~v~. This hypothesis remains to be confirmed.

Glycosylation
=============

Glycosylation is another important PTM that affects sodium channel function and expression. Glycosylation is a crucial step for protein biosynthesis and folding, but it is also involved in cell signaling, cell-cell adhesion, protection against proteolysis, and cellular development and immunity ([@B198]). Na~v~ α-subunits undergo important glycosylation steps in the endoplasmic reticulum and Golgi apparatus ([@B282]; [@B245]), a process involving the sequential addition of *N*-acetylglucosamines capped by sialic acid residues, and the further addition of diverse oligosaccharide chains. Glycosylation can account for 5% ([@B56]) to 30% of the α-subunit's molecular weight ([@B192]), depending on the isoform, with an estimated stoichiometry of around 100 sialic acid molecules per channel ([@B137]). Glycosylation is known to influence Na~v~ gating properties ([@B227]; [@B20]; [@B314]; [@B273]) by interfering with the electric field near the gating sensors ([@B20]; [@B62]). It was proposed that extracellular sialic acid residues, which are negatively charged at physiological pH, influence the sensitivity of the voltage sensor domains to the transmembrane electrical potential difference ([@B88]).

Only a few studies have investigated glycosylation of Na~v~s in the peripheral sensory nervous system. One reported that Na~v~1.9 is subject to important developmentally regulated glycosylation. This isoform is found in two different heavily glycosylated forms in neonatal rats, which have different gating properties as compared to the less glycosylated form of Na~v~1.9 in adult tissue ([@B273]). Another study reported that Na~v~1.7 is found in at least two different glycosylated forms in HEK293 cells: a heavily functional glycosylated form and a core-glycosylated immature form ([@B162]). The same authors later reported that a third intermediate glycosylated form is also present in HEK293 cells ([@B163]). Inhibition of glycosylation in *Xenopus* oocytes by tunicamycin also altered Na~v~1.3 gating properties ([@B299]). Whether these different patterns of α-subunit glycosylation lead to modification of Na~v~ function has yet to be investigated in peripheral chronic pain syndromes.

Ubiquitylation
==============

Ubiquitylation is another well-known PTM that negatively regulates the cell surface expression of many different plasma membrane proteins ([@B258]). Ubiquitylated proteins that are internalized through this pathway are either degraded or recycled ([@B250]; [@B6]; [@B54]). Ubiquitin is a small and highly conserved polypeptide of 76 amino acids that is covalently attached to the lysine residues of the targeted protein. Three enzymatic successive steps are required to ubiquitylate a protein ([@B218]): (1) ubiquitin is first activated by a ubiquitin-activating enzyme (E1) in an ATP-dependent manner, (2) ubiquitin is then transferred to a ubiquitin-conjugating enzyme (E2) via a thioester bond, (3) this complex further interacts with an ubiquitin-protein ligase (E3) that eventually ubiquitylates the substrate protein.

The first and probably best-described protein that undergoes ubiquitylation is ENaC ([@B5]; [@B233]). The ENaC subunit possesses a PY motif. Mutating this motif is sufficient to generate a hypertensive phenotype, known as Liddle's Syndrome ([@B242]), which involves increased ENaC function ([@B99]). Nedd4 and Nedd4-2 proteins where shown to bind to ENaC's PY motif on large members of the E3 ubiquitin ligase family ([@B143]; [@B193]), leading to its internalization ([@B5]; [@B119]). This process is impaired in Liddle's syndrome.

Most Na~v~s possess a PY motif at their α-subunit C-terminal, making them potential substrates for Nedd4-2 dependent ubiquitylation ([@B3]; [@B164]). The first sodium channel isoform described to be regulated by Nedd4-2 was Na~v~1.5. Regulation was demonstrated in both *cell expression systems* and cardiac tissue ([@B274]). Na~v~1.7 and Na~v~1.8 also possess a PY motif and were shown to be negatively regulated by Nedd4-2 in both *Xenopus* oocytes ([@B103]) and HEK293 cells ([@B162]). The functional significance of Na~v~ regulation by Nedd4-2 was previously demonstrated in chronic pain syndromes. In an animal model of neuropathic pain, ubiquitin ligase expression was robustly reduced in both mice ([@B162]) and rats ([@B37]). Na~v~1.7 and Na~v~1.8 expression were increased as a consequence of Nedd4-2 downregulation. The causal link between Nedd4-2 downregulation and Na~v~1.7/Na~v~1.8 upregulation was demonstrated using both tissue specific knockout and viral overexpression of Nedd4-2, leading to hyper- and hypo- pain sensing phenotypes, respectively ([@B162]). The reduction of Nedd4-2 might also increase membrane expression of other Na~v~s, with the exception of Na~v~1.9 which lacks the PY motif, ([@B3]), and other ion channels expressed in sensory neurons that are also substrates for this ubiquitin ligase ([@B31]). Na~v~1.6 was also regulated by Nedd4-2 in mouse hippocampal neurons, a process dependent on the concomitant p38-mediated phosphorylation of this sodium channel isoform ([@B107]). Whether Nedd4-2 downregulation in neuropathic pain is due to the inflammatory soup or to another mechanism remains to be investigated.

Methylglyoxal
=============

A recent study unraveled a new mechanism accounting for painful peripheral neuropathy in diabetes. The authors showed that the concentration of methylglyoxal, an endogenous degradation product of excessive glycolysis ([@B267]), is increased in patients suffering from diabetes. Since peripheral nerves have low levels of enzymes that metabolize methylglyoxal ([@B24]), its accumulation in the sensory system was proposed to account for pain hypersensitivity. The authors reported that the methylglyoxal effect on excitability was through its binding to Na~v~1.8 within the DIII-DIV linker on an arginine residue, which reduced channel inactivation ([@B23]), leaving the channel in an excitable state. In sciatic nerve biopsies isolated from patients with diabetes and from those who had amputations due to peripheral artery disease, the authors observed an increase of Na~v~1.8 modification by methylglyoxal when compared to controls. It was proposed that this PTM was specific to Na~v~1.8 in regards to sodium channel regulation, but the authors demonstrated that methylglyoxal can also have an effect on pain pathways by depolarizing nociceptive neurons, and increasing GCRP release and COX-2 expression.

Post-Translational Modification Of Na~v~ Protein Partners
=========================================================

Many protein partners are known to interact with typical pain isoforms and undergo PTM. Evidence is lacking which demonstrates a direct effect between protein partners' PTMs and concomitant modification of Na~v~ expression or function. In the following chapter, we will discuss the potential partners that undergo PTMs that are known to regulate Na~v~1.7, Na~v~1.8, and Na~v~1.9.

β--Subunits
-----------

β--subunits are important regulators of Na~v~s. They are implicated in neuropathic pain and are subject to PTMs. β-subunits regulate α-subunit gating properties by direct steric interactions that interfere with the voltage-sensor ([@B318]). Even though the effects of the different β-subunits on biophysical properties give rise to conflicting results ([@B210]; [@B238]; [@B252]; [@B199]; [@B94]; [@B278], [@B277]; [@B318]), partially due to the different cell types used, the literature clearly demonstrates that β-subunits regulate Na~v~ gating. β-subunits can also affect the Na~v~ current in an *ex vivo* nociceptive neuron primary culture, as highlighted by the decreased *I*~Na~ current recorded from *SCN1B* and *SCN2B* knockout animals ([@B180], [@B179]). *SCNB* knockout animals also demonstrated abnormal pain sensing, confirming that modulating Na~v~ function ultimately modulates pain signaling ([@B216]; [@B180], [@B179]). Moreover, β1-, β2-, and β3-subunit expression levels are increased in different animal models of pathological pain ([@B247]; [@B60]; [@B216]), highlighting their potential implication in modulating cellular excitability. Auxiliary β-subunits are themselves substrates for glycosylation ([@B134]), which ultimately modulates α-subunit function ([@B145]; [@B144]). β-subunits can also be phosphorylated, i.e., the phosphorylation of Tyr181 is necessary for the interaction with ankyrin, another Na~v~ protein partner ([@B186]). Whether altered glycosylation or phosphorylation of the β-subunits could be implicated in pathological pain has, at least to our knowledge, never been investigated.

Nedd4-2
-------

Nedd4-2, a potent regulator of Na~v~s in the sensory nervous system, also undergoes several PTMs, particularly by kinases which alter its function. Most of these pathways have been investigated in the Nedd4-2 regulation of ENaC ([@B253]). Whether a similar action also occurs on the sodium channels in the sensory system remains to be determined. Pathways that lead to Nedd4-2 PTMs are the same pathways as those activated in chronic pain syndromes. For instance, phosphorylation of Nedd4-2 by PKA was demonstrated to decrease Nedd4-2 ubiquitylating efficiency ([@B254]). In addition to its direct effect on Na~v~s, it is probable that PKA activation also indirectly leads to an increase of Na~v~ channels at the membrane by impeding the downregulatory role of Nedd4-2. It has been well documented that cytokine signaling leads to NF-κB activation in inflammatory processes. These signals first activate the IκB kinase \[an inhibitor of nuclear factor κB (NF-κB)\] (IKK) via phosphorylation, which then phosphorylates and inactivates IκB inhibitory proteins. IKKβ, a subunit of IKK that is expressed in unmyelinated fibers, then binds and phosphorylates Nedd4-2 ([@B87]). Finally, NGF, another inflammatory mediator ([@B170]) also known to positively regulate Na~v~s mRNA expression ([@B269]; [@B101]), triggers a cascade after binding to the TrkA receptor, which ultimately leads to Nedd4-2 phosphorylation ([@B13]). Pro-inflammatory molecules likely negatively regulate Nedd4-2 activity in nociceptive neurons following inflammation, leading to an increase in Na~v~ expression at the membrane.

Collapsin Response Mediator Protein 2 (CRMP2)
---------------------------------------------

Collapsin response mediator protein 2 (CRMP2) is a protein initially identified to be important for axonal outgrowth ([@B133]). It is now known to be important for modulating ion channel trafficking ([@B33]; [@B53]). CRMP2 is the secondary target of the anti-epileptic drug lacosamide ([@B90], [@B91]) and can directly bind to Na~v~s ([@B283]), modulating the channel's slow inactivation. In a recent study carried out in both HEK293 cells and sensory neurons, it was demonstrated that CRMP2 can be SUMOylated, which affects Na~v~1.7 trafficking ([@B86]). Whether SUMOylation of CRMP2 plays a role in pathological pain via the alteration of Na~v~1.7 trafficking remains to be investigated.

There are many other well described proteins, i.e., contactin ([@B225]; [@B148]), ankyrin ([@B185]), spectrin ([@B21]), dystrophin, and syntrophin ([@B109]; [@B4]) among others ([@B248]), that interact with Na~v~s and modulate their function and cell surface expression. Kinases are themselves substrates for PTMs that can modify their function in important ways. All of these proteins are subject to PTMs, which may impact the control of Na~v~ function and expression in peripheral chronic pain syndromes.

Ptms Modulate Na~v~ Transcription
=================================

In studies carried out in adrenal chromaffin cells, which express relatively high levels of Na~v~1.7 ([@B156]; [@B268], [@B269]; [@B114]; [@B281], [@B280]), a role for PTMs in controlling Na~v~ transcription was proposed. ERK kinases were shown to positively regulate Na~v~1.7 expression at the membrane by modulating their mRNA stability ([@B302]). Conversely, PKC𝜀 kinase activation destabilized Na~v~1.7 mRNA, contributing to Na~v~1.7 negative regulation of the steady-state levels at the plasma membrane ([@B303]). Whether similar mechanisms occur in sensory neurons has not been reported.

Discussion
==========

Na~v~s expression and function are dysregulated in peripheral inflammatory pain, nerve injury induced neuropathic pain, metabolic, infectious, toxic or inherited painful neuropathies. Peripheral mechanisms for initiation and maintenance of pain is partially due to the release of inflammatory molecules that trigger different signaling cascades and leads to the activation of enzymes with diverse functions. In turn, these enzymes will post-translationally modify Na~v~ function and expression, ultimately impacting nociceptive neuronal hyperexcitability and pain. Most knowledge of such mechanisms comes from the kinase field, but since Na~v~s are large proteins composed of over 2000 amino acids, they possess a plethora of domains that could be subject to PTMs. It is likely that PTM's contribution to chronic pain syndromes are still under-estimated and should be further investigated. In this review, we not only discussed proven Na~v~ PTMs implications in pathological pain but also other potential relevant PTMs, which will eventually open new avenues for a deeper understanding of chronic pain syndromes. Together with the development of more efficient and specific pharmacological agonists and antagonists targeting PTM effectors, new genome engineering tools will facilitate the generation of knock-in mice with mutations on PTM sites or on the PTM effectors themselves. This will hopefully help confirm and identify new pathways that regulate Na~v~ function and expression.

The pharmaceutical industry is attempting to develop highly selective drugs that block Na~v~1.7, Na~v~1.8, or Na~v~1.9, but with unfortunately little progress. This is partially due to the fact that Na~v~s are well-conserved proteins, and non-specific blockers are bound to have many dramatic side effects. Rather than targeting and blocking the sodium channels themselves, regulating the function or expression of sodium channels, which may have more subtle effects on excitability, might prove to be an interesting alternative to treat chronic pain. From this perspective, more effort should be focused on targeting PTM pathways, as exemplified by the anti-TNF-α drug, which is promising and still in expansion ([@B170]). Pharmacological targeting of the MAPK pathway has already been shown to have an analgesic effect ([@B270]), and many other kinases are currently in pre-clinical or clinical studies ([@B141]). Other promising avenues include the use of scavengers of methylglyoxal ([@B23]) or the use of gene therapy to restore Nedd4-2 ubiquitylating function, which have proven to be efficient in relieving pain in animal models of chronic pain. Altogether, it is important to further characterize the known PTM effects on Na~v~s and to identify new PTMs in order to gain insight into the development of pathological pain.
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